CCM
BMY.RT

CAAS Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

CAAS Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-489,170
Closed -$338K – 1502
2020
Q4 		$338K Hold
489,170
– – ﹤0.01% 719
2020
Q3 		$1.1M Buy
489,170
+223,040
+84% +$637K 0.03% 331
2020
Q2 		$953K Hold
266,130
– – 0.03% 273
2020
Q1 		$1.01M Buy
+266,130
New +$877K 0.11% 133

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

CAAS Capital Management's BMY.RT Position: Q1 2021 in Review

CAAS Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 489,170 shares — an estimated $338K sold.

CAAS Capital Management first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $1.1M in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • CAAS Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 489,170 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $338K.
  • CAAS Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • CAAS Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.1M in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.